医学
抗生素
囊性纤维化
β-内酰胺
药店
抗菌化疗
基础(证据)
协商一致会议
抗菌剂
重症监护医学
临床药理学
临床微生物学
化疗
内科学
家庭医学
药理学
政治学
微生物学
法学
生物
作者
Lisa T. Hong,Kevin J. Downes,Alireza FakhriRavari,Jacinda C. Abdul‐Mutakabbir,Joseph L. Kuti,Sarah C J Jorgensen,David C. Young,Mohammad H. Al‐Shaer,Matteo Bassetti,Robert A. Bonomo,Mark J. Gilchrist,Soo Min Jang,Thomas P. Lodise,Jason Alexander Roberts,Thomas Tängdén,Athena F. Zuppa,Marc H. Scheetz
摘要
Intravenous β-lactam antibiotics remain a cornerstone in the management of bacterial infections due to their broad spectrum of activity and excellent tolerability. β-lactams are well established to display time-dependent bactericidal activity, where reductions in bacterial burden are directly associated with the time that free drug concentrations remain above the minimum inhibitory concentration (MIC) of the pathogen during the dosing interval. In an effort to take advantage of these bactericidal characteristics, prolonged (extended and continuous) infusions (PI) can be applied during the administration of intravenous β-lactams to increase time above the MIC. PI dosing regimens have been implemented worldwide, but implementation is inconsistent. We report consensus therapeutic recommendations for the use of β-lactam PI developed by an expert international panel with representation from clinical pharmacy and medicine. This consensus guideline provides recommendations regarding pharmacokinetic and pharmacodynamic targets, therapeutic drug monitoring considerations, and the use of PI β-lactam therapy in the following patient populations: severely ill and nonseverely ill adult patients, pediatric patients, and obese patients. These recommendations provide the first consensus guidance for the use of β-lactam therapy administered as PIs and have been reviewed and endorsed by the American College of Clinical Pharmacy (ACCP), the British Society for Antimicrobial Chemotherapy (BSAC), the Cystic Fibrosis Foundation (CFF), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), the Infectious Diseases Society of America (IDSA), the Society of Critical Care Medicine (SCCM), and the Society of Infectious Diseases Pharmacists (SIDP).
科研通智能强力驱动
Strongly Powered by AbleSci AI